Summary
The AI statements provided are not supported or verifiable from the supplied BREO ELLIPTA prescribing information excerpts (sections 1, 2, 4, 5, 6, 7, 8, 10, 17). Several product-patent/generic-availability and sales/Paragraph IV challenge claims are outside the label and cannot be validated against it, but they were nevertheless presented as factual statements.
Category Scores
Accurate Statements
Unsupported Statements
No approved generic version of Breo Ellipta (fluticasone furoate/vilanterol) exists in the US as of 2024.
Not supported by the provided BREO ELLIPTA prescribing information excerpts; label excerpts contain no information about generic availability.
Breo Ellipta remains under patent protection in the US as of 2024.
Not supported by the provided prescribing information excerpts; label excerpts contain no patent-status information.
GSK holds patents on Breo Ellipta until at least 2030.
Not supported by the provided prescribing information excerpts; label excerpts contain no patent-expiration timelines.
The primary composition patent for Breo Ellipta expires in 2025.
Not supported by the provided prescribing information excerpts; label excerpts contain no patent-expiration details.
Secondary patents extend exclusivity for Breo Ellipta.
Not supported by the provided prescribing information excerpts; label excerpts contain no exclusivity/patent extension details.
No ANDA approvals for generics have been granted yet for Breo Ellipta.
Not supported by the provided prescribing information excerpts; label excerpts contain no ANDA approval status.
GSK has not launched an authorized generic for Breo Ellipta.
Not supported by the provided prescribing information excerpts; label excerpts contain no information about authorized generics.
No interchangeable biosimilars are approved for Breo Ellipta.
Not supported by the provided prescribing information excerpts; label excerpts contain no biosimilar/interchangeability information.
Breo Ellipta is a small-molecule combination, not a biologic.
Not supported by the provided prescribing information excerpts; label excerpts provided do not state the biologic/small-molecule classification.
Advair Diskus (fluticasone/salmeterol) has generics available since 2022.
Not supported by the provided prescribing information excerpts; label excerpts are specific to BREO ELLIPTA and contain no comparative generic-date information for other products.
Generics for Advair Diskus are about 80% lower cost.
Not supported by the provided prescribing information excerpts; label excerpts contain no pricing comparisons.
Symbicort (budesonide/formoterol) has a generic approved in 2022.
Not supported by the provided prescribing information excerpts; label excerpts contain no other-product generic approval timeline data.
There is no generic yet for Trelegy Ellipta.
Not supported by the provided prescribing information excerpts; label excerpts contain no information about Trelegy Ellipta generic availability.
Trelegy Ellipta is pricier than generics mentioned for other products.
Not supported by the provided prescribing information excerpts; label excerpts contain no pricing statements.
Breo Ellipta generated $2.2 billion in 2023 sales.
Not supported by the provided prescribing information excerpts; label excerpts contain no sales figures.
Over 20 Paragraph IV challenges from generics makers like Mylan and Teva are ongoing for Breo Ellipta.
Not supported by the provided prescribing information excerpts; label excerpts contain no Paragraph IV litigation status or named companies.
The ongoing Paragraph IV challenges could potentially allow generic entry after 2025 if successful.
Not supported by the provided prescribing information excerpts; label excerpts contain no legal/procedural claims about generic entry timing.
Contradictions
Important Omissions
Any claims or information related to BREO ELLIPTA’s FDA-approved clinical use (indications), dosage/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, or monitoring instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The supplied AI statements are primarily about patent/generic market status, pricing, sales, and litigation rather than prescribing information (dose, contraindications, warnings, interactions). These do not directly describe dosing or unsafe clinical steps, but they are unverified against the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most provided statements are not present in the supplied FDA label excerpts and cannot be verified against them (patent/generic availability, sales, and litigation claims).
Suggested Improvement
Evaluate only claims that directly relate to labeling content (e.g., indications, dosage/administration, contraindications, warnings/precautions, interactions, adverse reactions). Remove or qualify statements that are not contained in the prescribing information excerpts.